APA (7th ed.) Citation

Kaiser, M., Suvannasankha, A., Lee, D., Dlotko, E., Macleod, P., Boytsov, N., . . . McNamara, S. (2025). EE282 Quality-Adjusted Life Year (QALY) Results From a Cost-Effectiveness Model for Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Relapsed/Refractory Multiple Myeloma (RRMM). Value in Health, 28(6), S114. https://doi.org/10.1016/j.jval.2025.04.1881

Chicago Style (17th ed.) Citation

Kaiser, Martin, et al. "EE282 Quality-Adjusted Life Year (QALY) Results From a Cost-Effectiveness Model for Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Relapsed/Refractory Multiple Myeloma (RRMM)." Value in Health 28, no. 6 (2025): S114. https://doi.org/10.1016/j.jval.2025.04.1881.

MLA (9th ed.) Citation

Kaiser, Martin, et al. "EE282 Quality-Adjusted Life Year (QALY) Results From a Cost-Effectiveness Model for Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Relapsed/Refractory Multiple Myeloma (RRMM)." Value in Health, vol. 28, no. 6, 2025, p. S114, https://doi.org/10.1016/j.jval.2025.04.1881.